Antibody-drug conjugates in solid tumors: Efficacy, challenges, and opportunities
Nakul M Shah1, Funda Meric-Bernstam2
1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Antibody-drug conjugates (ADCs) have become an increasingly important component of the therapeutic landscape of many solid tumors. Currently, there are eight ADCs approved for solid tumors, with hundreds being developed and in clinical trials. Initially being approved in the advanced or metastatic settings, ADCs are also being incorporated as neoadjuvant or adjuvant therapies. In this review, we discuss the important components of ADC design in the context of clinical successes and failures. We further evaluate mechanisms of intrinsic and acquired resistance and strategies to overcome these barriers. Finally, we discuss the landscape of potential combination partners to increase efficacy of ADC therapies.
Insights
Antibody-drug conjugates (ADCs) are vital for treating solid tumors, with ongoing development and clinical trials. This review covers ADC design, resistance mechanisms, and combination strategies for enhanced efficacy.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Antibody-drug conjugates (ADCs) are a significant therapeutic class for solid tumors.
- Eight ADCs are currently approved, with hundreds more in development and clinical trials.
- ADCs are being explored in early-stage (neoadjuvant/adjuvant) settings, not just advanced disease.
Purpose of the Study:
- To review key components of ADC design.
- To analyze clinical successes and failures of ADCs.
- To evaluate resistance mechanisms and combination strategies for ADCs.
Main Methods:
- Literature review of ADC clinical data.
- Analysis of ADC design principles.
- Evaluation of resistance pathways and potential combination therapies.
Main Results:
- ADCs show promise but face challenges in clinical application.
- Understanding ADC design is crucial for therapeutic success.
- Resistance mechanisms and combination therapies are key areas for improvement.
Conclusions:
- ADCs represent a rapidly evolving and important therapeutic modality for solid tumors.
- Strategies to overcome resistance and enhance efficacy through combinations are critical for future ADC development.
- Continued research into ADC design and application is essential for expanding their role in cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...